Bruker Co. (NASDAQ:BRKR) Given Average Recommendation of “Moderate Buy” by Brokerages

Bruker Co. (NASDAQ:BRKRGet Free Report) has been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $79.36.

A number of brokerages have recently commented on BRKR. Citigroup reduced their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Barclays reduced their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. TD Cowen cut their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th.

Get Our Latest Analysis on BRKR

Bruker Trading Down 2.6 %

Shares of NASDAQ BRKR opened at $54.49 on Friday. Bruker has a fifty-two week low of $54.33 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The company has a market cap of $8.26 billion, a price-to-earnings ratio of 26.20, a PEG ratio of 2.68 and a beta of 1.20. The business’s 50 day moving average price is $62.85 and its 200-day moving average price is $65.61.

Bruker (NASDAQ:BRKRGet Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.74 earnings per share. On average, sell-side analysts expect that Bruker will post 2.4 earnings per share for the current year.

Institutional Investors Weigh In On Bruker

Several institutional investors have recently bought and sold shares of BRKR. First Horizon Advisors Inc. lifted its holdings in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares during the last quarter. Covestor Ltd raised its stake in Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the last quarter. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares during the last quarter. Finally, Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker during the second quarter valued at about $52,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

(Get Free Report

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Recommended Stories

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.